



Changes to the Contract Drugs List (CDL)

Effective June 1, 2022

The below changes have been made to the Contract Drugs List, effective June 1, 2022.

For more information, see the [Contract Drugs List](#) on the Medi-Cal Rx Web Portal.

Drug Name	Description	Effective Date
Abacavir Sulfate/Dolutegravir/Lamivudine	Additional formulation (tablets for oral suspension) added with restrictions.	June 1, 2022
Acyclovir	Additional formulation (oral suspension) added.	June 1, 2022
Baloxavir Marboxil	Tablets (20 mg) end dated.	June 1, 2022
Ciprofloxacin	Diagnosis and age restrictions removed from oral suspension.	June 1, 2022
Ciprofloxacin HCL	Restrictions removed from tablets.	June 1, 2022
Dexamethasone	Additional formulation (liquid drops) added to the CDL.	June 1, 2022
Fluconazole	Additional formulation (suspension) added.	June 1, 2022
Fluticasone Propionate	Oral formulations moved to Anti-Asthmatics section.	June 1, 2022
Indinavir sulfate	End dated.	June 1, 2022
Lenvatinib	Additional strength (4 mg) added.	June 1, 2022
Levocarnitine SF	Added to the CDL.	June 1, 2022
Levofloxacin	Additional formulation (oral solution) added to the CDL.	June 1, 2022

Drug Name	Description	Effective Date
Melphalan flufenamide	Injection end dated.	June 1, 2022
Metronidazole Vaginal	Labeler code restriction (99207) removed from vaginal gel, 70 grams.	June 1, 2022
Nivolumab, Relatlimab	Added to the CDL with restrictions.	June 1, 2022
Patiromer	Added to the CDL with a restriction.	June 1, 2022
Sevelamer Carbonate	Added to the CDL.	June 1, 2022
Sevelamer Hydrochloride	Restrictions removed.	June 1, 2022
Sodium Chloride	Additional strengths (0.45%, 3.5%, 6%, 10%) added.	June 1, 2022
Umbralisib	End dated.	June 1, 2022